If you're wondering why not even one Shigella vaccine has been approved yet, here's why. Know about the pipeline and why shigella matters in this infographic story #pharmaceutical #Health #VaccinesWork #data insights.citeline.com//scrip/r-and-d…

This affects us all who think, write, create. Will there be motivation to do this any more with AI using all that you created without any financial reward for creators? #AI #copyright #Creators #Legal technologyreview.com/2025/07/01/111…

Don't miss this great analytical and opinion piece from In Vivo. "Pharma’s Dance With Trump Risks Distracting From Longer-Term Threats" Citeline In Vivo, Citeline Commercial #Tariffs #Pharmaceutical #BusinessStrategy insights.citeline.com//in-vivo/marke…

Well… it’s happened… massive deal with AbbVie…. Upfront of $700m .. & $1.25bn … in dev, reg, commercial milestones…..Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma insights.citeline.com/scrip/focus-on…

AbbVie, Ichnos Glenmark in deal for trispecific T-cell engager. $700m upfront, upto $1.2bn milestone payments, royalties for exclusive rights to develop, manufacture, commercialize ISB 2001 across North America, Europe, Japan, Greater China #Deals #Biotech bseindia.com/xml-data/corpf…

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025 insights.citeline.com//scrip/busines…

Attention deal seekers - Merck CEO Rob Davis says pursuit of more deals remains even after $10bn deal to buy Verona Pharma. Keytruda to face 2028 patent cliff - contributed 46% of 2024 sales #deals #pharmaceutical #acquisition insights.citeline.com//scrip/busines…

What is Lupin’s strategy in developing a Cimzia biosimilar and partnering Zentiva for it? #research #pharmaceutical #BusinessNews insights.citeline.com//scrip/r-and-d…

Aside from multiple sizable global out-licensing deals, Korean bioventures saw a cancellation of other alliances, updated their pipelines and reported clinical trial progress in 2Q, while domestic IPO sentiment also improved, reports Scrip, Citeline Commercial. insights.citeline.com/scrip/focus-on…

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist insights.citeline.com//scrip/busines…

Quick Listen: Scrip’s Five Must-Know Things — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3ypm9 vist.ly/3ypma

My colleague Lisa Takagi reported on a Beijing court sentencing an Astellas employee and Japanese national to prison time #law #Pharmaceutical #Japan

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion, reports Scrip, Citeline Commercial. insights.citeline.com/scrip/business…

The latest in the never-ending changes at US FDA ever since Trump assumed office. Vinay Prasad Out At US FDA, Sarah Karlin-Smith reports Citeline #regulatory #FDA #Biotech insights.citeline.com//pink-sheet/ag…

Direct sales to patients, cutting out PBMs seems to be an idea gathering steam in the US. Now, Sanofi CFO says its ‘certainly worth considering’. Citeline #Pharmaceuticals #business #strategy insights.citeline.com//scrip/busines…

Why does Aurobindo expect US-based Lannett's acquisition to pass FTC scrutiny? How does it help to reduce tariffs? Read to know #business #Tariffs #Acquisition insights.citeline.com//scrip/busines…

Quick Listen: Scrip’s Five Must-Know Things insights.citeline.com//scrip/podcast…

Always great to have a vote of confidence from a person you look up to. Thanks Ian Haydock

Quick Listen: Scrip’s Five Must-Know Things — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/43nvi vist.ly/43nvj